In the article, Now, make way for the biotech copycats, the Economic Times reports that generic drug companies are already making preparations to bring "biosimilar" drugs to market. This article reports that the patents covering seven molecules including EPO, human insulin, and granulocyte colony stimulating factor will expire before 2010. Patent practioner Kausalya Santhanam indicates that it is expected that a bill will be introduced in the United States clarifying the various terms for introducing a biosimilar. Large biotech companies have been lobbying against such a bill, arguing that the biosimilar of a generic drug company is not the same as an innovator's product. Sarabjit Kour Nangra, Vice-President Research, of Angel Broking is quoted: "a company making a biosimilar will not use the same cell line or manufacturing process as the maker of the original drug, and the slightest change may have dramatic consequences on the drug's characteristics".

For more information, please see: